Terms: = Kidney tumors AND PR, PGR, progesterone receptor AND Treatment
331 results:
1. Cobimetinib Plus Vemurafenib in Patients With Solid tumors With
Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
[TBL] [Abstract] [Full Text] [Related]
2. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
[TBL] [Abstract] [Full Text] [Related]
3. Protocol for a mixed-method study to assess chronic cough in patients with renal cell carcinoma: the prevalence, impact on quality of life, trigger and potential clinical application of chronic cough as an early screening tool in patients with kidney cancer.
Smith W; Loizidou M; Mazzone S; Mumtaz F; Gurusamy K; Ranieri V; Tran MG
BMJ Open; 2023 Nov; 13(11):e074077. PubMed ID: 37949629
[TBL] [Abstract] [Full Text] [Related]
4. Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer.
He S; Wang L; Sun Y; Du H; Yu X
Front Immunol; 2023; 14():1270828. PubMed ID: 37915573
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
Harada KI; Sato R; Bando Y; Sano A; Matsushita Y; Tamura K; Terakawa T; Furukawa J; Fujimoto N; Fujisawa M; Miyake H
Int J Urol; 2023 Sep; 30(9):772-777. PubMed ID: 37345413
[TBL] [Abstract] [Full Text] [Related]
6. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control.
Sharma H; Moturi KR; Pankratz VS; Yilmaz E; Gbolahan OB; Kumar A; Hashemi-Sadraei N
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8673-8680. PubMed ID: 37115270
[TBL] [Abstract] [Full Text] [Related]
7. Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis.
Haaker L; Baldewijns M; De Wever L; Albersen M; Debruyne PR; Wynendaele W; De Meerleer G; Beuselinck B
Clin Genitourin Cancer; 2023 Aug; 21(4):442-451. PubMed ID: 36997468
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study.
Lu H; Ye Q; Zheng C; Fan L; Xia X
BMC Cancer; 2023 Mar; 23(1):270. PubMed ID: 36964538
[TBL] [Abstract] [Full Text] [Related]
9. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
Li H; Sahu KK; Brundage J; Benson M; Swami U; Boucher KM; Gupta S; Hawks J; Sirohi D; Agarwal N; Maughan BL
Oncologist; 2023 Aug; 28(8):737-e693. PubMed ID: 36952231
[TBL] [Abstract] [Full Text] [Related]
10. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Atkins MB; Jegede OA; Haas NB; McDermott DF; Bilen MA; Stein M; Sosman JA; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Signoretti S; Denize T; Cimadamore A; Wu CJ; Braun D; Einstein D; Catalano PJ; Hammers H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948504
[TBL] [Abstract] [Full Text] [Related]
11. Baseline and Dynamic Changes in Hemoglobin Levels Predict treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study.
Yang YH; Ansel S; Meerveld-Eggink A; Jackson-Spence F; Rallis K; Brian P; Choy J; Sng C; Adeniran P; Amin J; Galope S; Anderson N; Bex A; Powles T; Venugopal B; Szabados B
Clin Genitourin Cancer; 2023 Aug; 21(4):e242-e251. PubMed ID: 36922286
[TBL] [Abstract] [Full Text] [Related]
12. Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective treatment for Lung Carcinoma.
Ji X; Jing X; Liu Y; Huang J; Yang S; Yun Y
Dis Markers; 2022; 2022():2483816. PubMed ID: 36277984
[TBL] [Abstract] [Full Text] [Related]
13. ♣Evaluation of clinicopathological profiles and development of a risk model in renal epithelioid angiomyolipoma patients: a large-scale retrospective cohort study.
Anwaier A; Xu WH; Tian X; Ding T; Su JQ; Wang Y; Qu YY; Zhang HL; Ye DW
BMC Urol; 2022 Sep; 22(1):148. PubMed ID: 36096809
[TBL] [Abstract] [Full Text] [Related]
14. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients.
Hanania HL; Lewis DJ
J Dermatolog Treat; 2022 Dec; 33(8):3119-3126. PubMed ID: 36018250
[TBL] [Abstract] [Full Text] [Related]
15. Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.
Fendler WP; Pabst KM; Kessler L; Fragoso Costa P; Ferdinandus J; Weber M; Lippert M; Lueckerath K; Umutlu L; Kostbade K; Mavroeidi IA; Schuler M; Ahrens M; Rischpler C; Bauer S; Herrmann K; Siveke JT; Hamacher R
Clin Cancer Res; 2022 Oct; 28(19):4346-4353. PubMed ID: 35833949
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma.
Zhou L; Liu Y; Mo J; Cui C; Chi Z; Si L; Kong Y; Yan X; Li S; Wu X; Li J; Xu H; Cao D; Guo J; Sheng X
Urol Oncol; 2022 Aug; 40(8):385.e1-385.e8. PubMed ID: 35773144
[TBL] [Abstract] [Full Text] [Related]
17. Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma.
Shirotake S; Miyama YU; Baba Y; Tajima H; Okada Y; Nakazawa K; Usami Y; Yasuda M; Igarashi D; Kaneko GO; Kanao K; Oyama M; Nishimoto K
Anticancer Res; 2022 May; 42(5):2727-2735. PubMed ID: 35489743
[TBL] [Abstract] [Full Text] [Related]
18. Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.
Guiard E; Baldini C; Pobel C; Assi T; Bernard-Tessier A; Martin-Romano P; Hollebecque A; Verlingue L; Geraud A; Michot JM; Armand JP; Soria JC; Massard C; Ammari S
Eur J Cancer; 2022 May; 167():42-53. PubMed ID: 35378410
[TBL] [Abstract] [Full Text] [Related]
19. Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy.
Tatar G; Alçin G; Şengül Samanci N; Erol Fenercioglu Ö; Beyhan E; Çermik TF
Nucl Med Commun; 2022 Jun; 43(6):701-709. PubMed ID: 35362692
[TBL] [Abstract] [Full Text] [Related]
20. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Meric-Bernstam F; Tannir NM; Iliopoulos O; Lee RJ; Telli ML; Fan AC; DeMichele A; Haas NB; Patel MR; Harding JJ; Voss MH; Owonikoko TK; Carthon B; Srinivasan R; Bendell JC; Jenkins Y; Whiting SH; Orford K; Bennett MK; Bauer TM
Clin Cancer Res; 2022 Apr; 28(8):1540-1548. PubMed ID: 35140121
[TBL] [Abstract] [Full Text] [Related]
[Next]
